

★CO-LOCATED SESSION

[C4] Global Drug Development Strategy

April 14(Fri), 10:00-15:00 / Rm.E3

Most of Korean pharma and bio-ventures are getting focusing on Global new drug development. Therefore, global drug development strategy, as like new trend on US / EU market, is very important issue to support current development process. Therefore, We, Ginapath, would like to introduce our Know-how and experience with global pharma and authorities. the detailed topic is (Oncology drug development in pre-clinical trial / CNS drug development in pre-clinical trial / Peer Review in pre-clinical trial / SEND (Standard Exchange Non-clinical Data) introduction / New trend on global clinical phase I strategy) . Hope to see you soon shortly.

Session Chair Seung-Woo Song, CEO, Ginapath Co., Ltd

Speakers

10:00-10:10 Seminar Opening

Seung-Woo Song, CEO, Ginapath Co., Ltd

10:10-11:00 Oncology Drug Development in Pre-clinical Trial

Enrico Pesenti, CEO, Accelera

11:00-11:40 CNS Drug Development in Pre-clinical Trial

Atushi Fujiwara, Study Director, Research Administration Dept., INA Research

11:40-12:40 Session Break

12:40-13:20 Peer Review in Pre-clinical Trial

Klaus Weber, CEO, Anapath

13:20-14:00 SEND (Standard Exchange Non-Clinical Data)

Anzai Takayuki, Vice President, PDS Asia Pacific, PDS Lifescience

14:00-14:40 New Tend on Global Clinical Phase I Strategy

Marie Gilbert-Collet, Sales and Contract Manager, Eurofins OPTIMED

14:40-15:00 Seminar Closing

Seung-Woo Song, CEO, Ginapath Co., Ltd